RxDoctor Payments Data

Jessica Escobar

Nurse Practitioner · Fort Wayne, INNPI 1891880241

Payments from drug & device makers

$760in general payments, 2019–2025

Across 31 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$242
  • AstraZeneca$98
  • Lilly USA, LLC$95
  • Abbott$72
  • Insulet Corporation$58
  • Novo Nordisk$41
  • plus $155 from 6 others

What the payments were for

  • Food & beverage$69091%
  • Education$709%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$760 in reported general payments places this provider in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$29,696
Medicare patients
119
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide317$504,362
JardianceEmpagliflozin237$322,196
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog183$217,517
TrulicityDulaglutide102$173,520
MounjaroTirzepatide114$144,886
Tresiba Flextouch U-200Insulin Degludec101$118,110
FarxigaDapagliflozin Propanediol85$106,355
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog111$103,063
Humalog Kwikpen U-100Insulin Lispro159$91,548
Fiasp FlextouchInsulin Aspart (Niacinamide)43$63,376
Lantus SolostarInsulin Glargine,hum.Rec.Anlog297$61,110
Novolog FlexpenInsulin Aspart120$51,929
RybelsusSemaglutide26$50,603
JanuviaSitagliptin Phosphate52$46,912
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/731$42,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$41$573,201382 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$95$337,759284 claims
Boehringer IngelheimJardiance, Tradjenta$34$329,116249 claims
AstraZenecaFarxiga$98$106,35585 claims
Sanofi-aventis U.S. LLCLantus$17$9,34740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →